«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2022年01期

页码:

15-19

栏目:

论著

出版日期:

2022-02-20

文章信息/Info

Title:

Clinical analysis of photodynamic therapy in 24 patients with airway malignant tumors

作者:

师佩¹; 李文洁¹; 顾兴¹; 冯斐¹; 贾丽娟¹; 金发光²; 张涛²; 张红军¹

710100 西安,西安市胸科医院¹ 710038 西安,空军军医大学第二附属医院²

Author(s):

Shi Pei¹;  Li Wenjie¹;  Gu Xing¹;  Feng Fei¹;  Jia Lijuan¹;  Jin Faguang²;  Zhang Tao²;  Zhang Hongjun¹.

¹Department of Respiratory and Critical Care Medicine, Xi'an Chest Hospital, Xi'an 710100, China; ²Department of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an 710038, China

关键词:

气道恶性肿瘤;  光动力治疗;  临床分析

Keywords:

Malignant tumor of airway;  Photodynamc therapy(PDT);  Clinical benefit

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2022.01.004

摘要:

目的 回顾性分析经电子支气管镜腔内激光光动力疗法(photodynamic therapy, PDT)治疗的气道恶性肿瘤患者临床资料,探讨PDT治疗的规律性。方法 选择 2019年2月至 2021年3月由我院呼吸与危重症医学科进行PDT治疗的气道恶性肿瘤患者24例,分别对一般临床资料、PDT治疗情况和治疗后随访,以及治疗后存活患者和死亡患者的特征进行分析。结果 截止2021年8月7日,PDT治疗后获益最大的患者随访时长达13.2个月,远远大于PDT治疗后获益较小患者的随访时长总生存期(overall survival, OS)4.7个月(P=0.02)。前者以管腔壁型为主(80%),而后者以管腔内型为主(50%)(P=0.034)。前者腔内病变短于后者(中位数分别是3 cm和5 cm,P=0.03)。前者年轻、病程短、以腺样囊性癌为主,而后者年龄大、病程长、以鳞癌为主(P>0.05)。结论 管腔壁型、气道腔内病变短,以及年轻、病程短和肺腺样囊性癌的气道恶性肿瘤患者可能在PDT治疗中获益较多; 相反,管腔内型、气道腔内病变长,以及年老、病程长和非肺腺样囊性癌的气道恶性肿瘤患者可能在PDT治疗中获益较少。

Abstract:

Objective The clinical data of patients with airway malignant tumors treated by electronic bronchoscope intracavitary laser photodynamic therapy(PDT)were analyzed retrospectively, to explore the regularity of PDT treatment. Methods 24 patients with airway malignant tumors treated by PDT were recruited in the Department of Respiratory and Critical Care Medicine of our hospital from February 2019 to March 2021. The general clinical data, PDT treatment and follow-up after treatment, as well as the characteristics of living and dead patients after treatment were analyzed. Results As of August 7, 2021, the patients with the greatest benefit after PDT treatment had been followed up for 13.2 months, which was much longer than length of follow-up in patients with less benefit after PDT treatment [the overall survival(OS)of 4.7 months](P=0.02). The former was mainly lumen wall type(80%), while the latter was mainly lumen type(50%)(P=0.034). The intraluminal lesions in the former were shorter than those in the latter(median 3 cm and 5 cm, respectively, P=0.03). The former was young, short course of disease and mainly adenoid cystic carcinoma, while the latter was old, long course of disease and mainly squamous cell carcinoma(P>0.05). Conclusion Patients with lumen wall type, short airway lesions, young, short course of disease and pulmonary adenoid cystic carcinoma may be benefit more from PDT treatment. On the contrary, patients with intraluminal type, long airway lesions, old age, long disease course and non- pulmonary adenoid cystic carcinoma may be benefit less from PDT treatment.

参考文献/References:

1 王国安, 吴宏成. 光动力治疗在呼吸道肿瘤中的临床应用[J]. 现代实用医学, 2020, 32(1): 7-8.
2 中国抗癌协会肿瘤光动力治疗专业委员会.呼吸道肿瘤光动力治疗临床应用中国专家共识[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 6-12.
3 凌一鸣. 激光-光化治疗的国内外应用研究进展[J]. 电子器件, 2003, 26(2): 107-110.
4 罗荣城, 廖旺军, 李黎波, 等. 肿瘤光动力治疗系-PHOTOFRIN/DIOMED(R)630PDT介绍[J]. 临床肿瘤学杂志, 2003, 8(4): 314-315.
5 李章生. 经纤维支气管镜腔内激光光动力疗法治疗晚期中央型肺癌疗效分析[J]. 中国医师进修杂志, 2007, 30(4): 51-52.
6 Kawashima O, Hirai T, Kamiyoshihara M, et al. Primary adenoid cystic carcinoma in the lung: report of two cases and therapeutic considerations[J]. Lung Cancer, 1998, 19(3): 211-217.
7 Travis WD, Travis LB, Devesa SS. Lung cancer[J]. Cancer, 1995, 75(Suppl 1): 191-202.
8 Turnbull AD, Huvos AG, Goodner JT, et al. The malignant potential of bronchial adenoma[J]. Ann Thorac Surg, 1972, 14(5): 453-464.
9 Chaudhry AP, Leifer C, Cutler LS, et al. Histogenesis of adenoid cystic carcinoma of the salivary glands. Light and electronmicroscopic study[J]. Cancer, 1986, 58(1): 72-82.
10 Lawrence JB, Mazur MT. Adenoid cystic carcinoma: a comparative pathologic study of tumors in salivary gland, breast, lung, and cervix[J]. Hum Pathol, 1982, 13(10): 916-924.
11 Molina JR, Aubry MC, Lewis JE, et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors[J]. Cancer, 2007, 110(10): 2253-2259.
12 Inoue H, Iwashita A, Kanegae H, et al. Matsumoto, Peripheral pulmonary adenoid cystic carcinoma with substantial submucosal extension to the proximal bronchus[J]. Thorax, 1991, 46(2): 147-148.
13 Ye MS, Ren C. Wang X, et al. Multi-Omics Characterization and Origin Assessment of Bilateral Lung Adenoid Cystic Carcinoma: A Case Report[J]. Cancer Manag Res, 2021, 13: 1981-1987.
14 Tang Z, Lin F, Xiao J, et al. Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma[J]. Front Oncol, 2021, 11: 605658.
15 MacRosty CR, Burks AC, Ghosh S, et al. Fatal Hemoptysis in a Patient With Left Mainstem Bronchus Squamous Cell Carcinoma Treated With Photodynamic Therapy: A Case Report and Review of the Literature[J]. J Bronchology Interv Pulmonol, 2019, 26(4): e60-e63.
16 Moghissi K, Dixon K, Thorpe JA, et al. Photodynamic therapy(PDT)in early central lung cancer: a treatment option for patients ineligible for surgical resection[J]. Thorax,2007, 62(5): 391-395.
17 Kimura M, Miyajima K, Kojika M, et al. Photodynamic Therapy(PDT)with Chemotherapy for Advanced Lung Cancer with Airway Stenosis[J]. Int J Mol Sci, 2015, 16(10): 25466-25475.
18 Dougherty TJ, Pucci MJ, Beaulieu D, et al. Frosco, 98th General Meeting of the American Society for Microbiology. May 17-21, 1998; Atlanta, GA[J]. Expert Opin Investig Drugs, 1998, 7(9): 1539-1557.
19 Ali AH, Takizawa H, Kondo K, et al. Follow-up using fluorescence bronchoscopy for the patients with photodynamic therapy treated early lung cancer[J]. J Med Invest, 2011, 58(1-2): 46-55.
20 Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy[J]. J Natl Cancer Inst, 1998, 90(12): 889-905.

备注/Memo

备注/Memo:

基金项目: 国家自然科学基金资助项目(81672269)
通信作者: 张红军, Email: jxzhjun@126.com

常用功能

更新日期/Last Update: 2022-02-20